Skip to main content
Advertising

Originally published Thursday, May 23, 2013 at 2:32 PM

  • Share:
           
  • Comments (0)
  • Print

Merck ends development of Parkinson's disease drug

Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

WHITEHOUSE STATION, N.J. —

Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Merck says it reviewed initial data from three late-stage clinical trials and did not find evidence preladenant was more effective than a placebo.

The company says it doesn't plan to file for marketing approval of the drug. It says the decision was not related to any safety problems.

Shares of Merck rose 62 cents to $47.33 on Thursday. The stock lost 21 cents to $47.12 in after-hours trading.

News where, when and how you want it

Email Icon

The summer is wide open.

The summer is wide open.

Follow our three-part "Washington's National Parks" series running through August 10 for an in-depth look at some of our local treasures.

Advertising

Advertising

The Seattle Times Historical Archives

Browse our newspaper page archives from 1900-1984


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►